Events & presentations

Corporate presentations, conference posters and scientific talks, together with the webcasts of quarterly results and corporate update calls. Every document is available to download.

80 events from 2017 to 2025. 39 carry a downloadable presentation or poster: 40 files in total.

Webcast recordings are hosted by the conference or webcast provider and open in a new tab. Older recordings may have expired at source; the presentation files below do not expire, because they are served from this site.

19 May 2025

Brainstorm Cell Therapeutics - Corporate Update

8 May 2025

Presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, May 6 - 10, 2025

30 December 2024

Brainstorm Cell Therapeutics - Corporate Update

11 December 2024

BrainStorm Cell Therapeutics KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS)

27 October 2024

Poster Presentations at the 2024 Annual NEALS Meeting October 21- 24, 2024

1 October 2024

Investor Presentation - October 2024

14 August 2024

Brainstorm Cell Therapeutics Second Quarter 2024 Earnings Call

8 July 2024

Corporate Mid-Year Update on NurOwn Program

9 April 2024

NurOwn Program Update Call Regarding Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

4 March 2024

Poster Presentation at the 2024 MDA Clinical and Scientific Conference

17 November 2023

6th Annual ALS Research Symposium

14 November 2023

Third Quarter 2023 Financial Results and Corporate Update Call

18 October 2023

Brainstorm Cell Therapeutics Investor Call

14 August 2023

Second Quarter 2023 Financial Results and Corporate Update Call

5 July 2023

New biomarker data from the Phase 3 trial, presented at the Gordon Research Conference

15 May 2023

First Quarter 2023 Financial Results and Corporate Update Call

30 March 2023

Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Update Call

27 March 2023

Brainstorm Investor Call

20 March 2023

Poster Presentation at the 2023 MDA Clinical and Scientific Conference

20 January 2023

13th Annual California ALS Research Summit

9 January 2023

Biotech Showcase 2023

14 November 2022

Third Quarter 2022 Financial Results and Corporate Update Call

6 November 2022

BrainStorm's Poster Presentation at the 21st Annual NEALS Meeting

26 October 2022

Poster Presentation at ECTRIMS 2022

7 October 2022

ALS One Research Symposium

15 August 2022

Second Quarter 2022 Financial Results and Corporate Update Call

2 June 2022

CMSC 2022 Meeting

1 June 2022

Poster Presentation at the ENCALS Meeting 2022, Edinburgh

26 May 2022

ISEV 2022 Annual Meeting, Lyon France

25 May 2022

ALS Drug Development Summit, Boston MA

16 May 2022

First Quarter 2022 Financial Results and Corporate Update Call

4 May 2022

ISCT 2022 Annual Meeting

28 March 2022

BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update

16 March 2022

Presentation at the MDA Clinical and Scientific Conference

27 January 2022

BrainStorm to Present at 12th Annual California ALS Research Summit

7 December 2021

BrainStorm to Present New Biomarker Data on NurOwn at the 32nd International Symposium on ALS/MND

30 November 2021

BrainStorm to Present at the 4th Annual ALS ONE Research Symposium

15 November 2021

Brainstorm Cell Therapeutics Third Quarter 2021 Earnings Call

14 October 2021

BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS

6 October 2021

BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting

26 April 2021

BrainStorm First Quarter 2021 Financial Results and Corporate Update

26 February 2021

10th Annual SVB Leerink Global Healthcare Conference

4 February 2021

BrainStorm-Cell Therapeutics Fourth Quarter and Fiscal Year 2020 Financial Results and Corporate Update

30 September 2020

Annual Northeast ALS (NEALS) Meeting

24 September 2020

WuXi Apptec- Collaborations That Transform Meeting (Multiple Sclerosis)

14 September 2020

2020 CIRM Grantee Meeting

9 September 2020

Advanced Therapies & Expo 2020

13 August 2020

Canaccord Genuity 40th Annual Growth Conference

5 August 2020

Financial Results for the Second Quarter of 2020 and Corporate Update

4 August 2020

Company non-confidential Presentation August 2020

8 July 2020

Key Opinion Leader (KOL) Webinar on the Company's Alzheimer's Disease (AD) Clinical Program

18 June 2020

Raymond James Human Health Innovations Conference

8 June 2020

Dr. Ralph Kern, MD, President and Chief Medical Officer, presents at Bio Digital 2020

7 May 2020

Brainstorm Cell Therapeutics First Quarter 2020 Investor Earnings Call

18 March 2020

BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19

18 February 2020

BrainStorm Cell Therapeutics - Fourth Quarter 2019 Investor Earnings Call

11 February 2020

BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference

24 January 2020

Dr. Ralph Kern at the ALS Research Forum, January 2020

13 January 2020

Brainstorm Cell Therapeutics Presentation at the 2020 Biotech Showcase

12 January 2020

Brainstorm Cell Therapeutics Presentation at the 3rd Annual Neuroscience Innovation Forum

6 January 2020

BrainStorm Cell Therapeutics at the 2nd Annual Sachs Associates Neuroscience Innovation Forum

4 December 2019

Brainstorm Cell Therapeutics Inc. 30th International Symposium on ALS/MND

14 November 2019

Brainstorm Cell Therapeutics Inc. Third Quarter 2019 Business Update Conference Call

29 October 2019

CEO Presentation at the Cell Series UK 2019 Conference

28 October 2019

CFO Presentation at the Dawson James Conference 2019

13 August 2019

Brainstorm Cell Therapeutics Inc. Second Quarter 2019 Business Update Conference Call

4 June 2019

Brainstorm Cell Therapeutics presentation at the Bio International Convention

30 May 2019

Brainstorm Cell Therapeutics Inc. at the 2019 CMSC Annual Meeting, Seattle WA

25 February 2019

Brainstorm Cell Therapeutics presentation at the 12th Annual European Life Sciences CEO Forum

7 January 2019

BrainStorm Cell Therapeutics presentations at the 37th Annual JP Morgan Healthcare Conference - 2019 Biotech Showcase

13 November 2018

Presentation at the Biotech and Money Investival Showcase 2018

5 September 2018

Brainstorm Presentation at the H.C. Wainwright & Co 20th Annual Investor Conference

23 July 2018

BrainStorm Cell Therapeutics - Second Quarter 2018 Earnings Call

14 May 2018

BrainStorm Cell Therapeutics - First Quarter 2018 Earnings Call

18 April 2018

CEO's Presentation at the 2018 ARM Cell & Gene Investor Conference

8 March 2018

Annual Financials Investor Call

13 February 2018

CEO's Presentation at the 2018 Bio CEO & Investor Conference

10 January 2018

CEO's Presentation at the 2018 Biotech Showcase Conference

18 September 2017

Investor Presentation - September 2017

1 October 2024

Investor Presentation October 2024 (alternate file)

BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.